Key result
Edoxaban proves non-inferior to warfarin for AF stroke prevention, lowering events ~21% while reducing major bleeding.
Why the study?
Atrial fibrillation complications include ischemic stroke, which can largely be prevented by direct oral anticoagulants, motivating a review of randomized trial and registry evidence for edoxaban.
Does edoxaban reduce the risk of stroke or systemic embolism compared to warfarin or placebo in patients with atrial fibrillation?
Population
Patients with AF
Comparison
Edoxaban vs warfarin or placebo
Design
Review of randomized trials and large registries
Authors
Loading...
May support edoxaban over warfarin in AF; leaves open confirmation in frail and Asian subgroups.
Does edoxaban reduce the risk of stroke or systemic embolism compared to warfarin or placebo in patients with atrial fibrillation?
Effect estimate: HR 0.79 (95% CI 0.63-0.99)
Absolute Event Rate: 1.18% vs 1.5%
p-value: p=<0.001 for noninferiority
This review highlights that edoxaban is an effective and safe alternative to warfarin for stroke prevention in diverse populations with atrial fibrillation, including elderly, frail, and Asian patients.
Joris R. de Groot (2025) conducted a review in Atrial fibrillation (n=21,105). Edoxaban vs. Warfarin was evaluated on Stroke or systemic embolism (SEE) (HR 0.79, 95% CI 0.63-0.99, p=<0.001 for noninferiority). Edoxaban 60/30 mg was non-inferior to warfarin for the prevention of stroke or systemic embolism (HR 0.79) in patients with atrial fibrillation, while significantly reducing major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: